Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008
Adalimumab treatment in patients with sarcoidosis: An open clinical trial using FDG-PET Source: Annual Congress 2010 - Sarcoidosis: from the bench to the bedside Year: 2010
Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis Source: Eur Respir J 2014; 44: 1296-1307 Year: 2014
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014
Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007
Infliximab therapy in patients with chronic progressive sarcoidosis – a retrospective follow-up study Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity Year: 2008
Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003
Changes of chest roentgenogram during a double blind randomized trial of infliximab for chronic pulmonary sarcoidosis Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002